Correlation of TAZ Immunohistochemistry Expression and Breast Carcinoma
International Journal of Clinical Oncology and Cancer Research
Volume 3, Issue 1, February 2018, Pages: 10-13
Received: Mar. 6, 2018; Accepted: Mar. 20, 2018; Published: Apr. 12, 2018
Views 1317      Downloads 67
Authors
Rafah Mohammed Jaffar Alkhateeb, Imamain Kadhymien Teaching Hospital, Baghdad, Iraq
Salim Rashid Alaubaidy, Pathology Department & Forensic Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
Article Tools
Follow on us
Abstract
Overexpression of TAZ induces cell transformation and tumor-forming ability in mammary epithelial cells. The deactivation of the Hippo pathway, which leads to up regulation of YAP and TAZ is frequently observed in many human cancers. The study samples included seventy four formalin-fixed, paraffin embedded tissue blocks which have been diagnosed as forty four cases of breast carcinoma and their lymph nodes. In the present study from 74 total cases, 33cases (44.6%) were showing TAZ marker positive while 41cases (55.4%) were showing negative immunohistochemistry for TAZ marker. Sub classification of malignant cases, 11 malignant breast cancer cases (25%) showed no TAZ expression, while 20 malignant cases (45.5%) were strongly positive for TAZ expression. There is significant correlation between breast carcinoma grade, stage and TAZ expression.
Keywords
Breast Tumor, Breast Cancer, TAZ Expression
To cite this article
Rafah Mohammed Jaffar Alkhateeb, Salim Rashid Alaubaidy, Correlation of TAZ Immunohistochemistry Expression and Breast Carcinoma, International Journal of Clinical Oncology and Cancer Research. Vol. 3, No. 1, 2018, pp. 10-13. doi: 10.11648/j.ijcocr.20180301.12
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Susan G. Komen. What is breast cancer? Fact for life. 2016; 2:16.
[2]
Han L, Shi S, Gong T, Zhang Z, Sun X. Cancer stem cells: therapeutic implications and perspectives in cancer therapy. Acta Pharmaceutica Sinica. B 2013; 3: 65-75.
[3]
Takahashi R, Takeshita F, Fujiwara T, Ono M, Ochiya T. Cancer stem cells in breast cancer. Cancers. 2011; 3: 1311-1328.
[4]
Sudol M, Sliwa K, Russo T. Functions of WW domains in the nucleus. FEBS Lett. Feb. 2001; 490(3):190–195.
[5]
Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong W. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. Apr. 2008; 68(8):2592–2598.
[6]
Hung Yi Kristal Kaan1, Siew Wee Chan1, Siew Kim Joyce Tan1, Fusheng Guo1, Chun Jye Lim1, Wanjin Hong1 & Haiwei Song"Crystal structure of TAZ-TEADcomplex reveals a distinctinteraction mode from that of YAPTEAD complex", scientific reports. 2017 may.
[7]
D. B. SeligsonEpithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma Clin. Cancer Res., 10 (2004), pp. 2659-2669.
[8]
Laoukili, J., Alvarez-Fernandez, M., Stahl, M., and Medema, R. H. FoxM1 is degraded at mitotic exit in a Cdh1-dependent manner. Cell Cycle 7.2008b. 2720–2726.
[9]
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011.20, 620–634.
[10]
Wang, I. C., Chen, Y. J., Hughes, D., Petrovic, V., Major, M. L., Park, H. J., et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 2005.25, 10875–10894.
[11]
Laoukili, J., Kooistra, M. R., Bras, A., Kauw, J., Kerkhoven, R. M., Morrison, A., et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 2005.7, 126–136.
[12]
Singh, B., Gogineni, S. K., Sacks, P. G., Shaha, A. R., Shah, J. P., Stoffel, A., et al. Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. Cancer Res.2010. 61, 4506–4513.
[13]
Pilarsky, C., Wenzig, M., Specht, T., Saeger, H. D., and Grutzmann, R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 2004.6, 744–750.
[14]
Jing Zhang, Kundong ZhangLisheng Zhou, Weidong Wu, Tao Jiang, Jun Cao, Kejian, Huan, Zhengjun Qiu, Chen Huang. Expression and potential correlation among Forkhead box protein M1, Caveolin-1 and E-cadherin in colorectal cancer. oncology letters. July 28, 2016.
[15]
Aleksandra Glapa1, Aleksandra Nijak. TAZ oncogene as a prognostic factorin breast cancer. Journal of Medical Science.2015. 2 (84).
[16]
Marcello Maugeri-Saccà a, b, Ruggero De Maria. Hippo pathway and breast cancer stem cells. Critical Reviews in Oncology/Hematology 99 (2016) 115–122.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186